平均依从性增强型蛋白酶抑制剂治疗，而不是漏服剂量模式，作为 HIV RNA 复制的预测指标。
Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication.
机构信息
Department of Clinical Research and Biostatistics, Côte de Nacre University Hospital, Caen F-14033, France.
出版信息
Clin Infect Dis. 2010 Apr 15;50(8):1192-7. doi: 10.1086/651419.
Abstract
Consecutive missed doses may differentially impact the efficacy of antiretroviral therapy associated with the use of a nonnucleoside reverse-transcriptase inhibitor (NNRTI) and a ritonavir-boosted protease inhibitor (PI). In a cohort of 72 subjects receiving a boosted PI, average adherence to dosage was a better predictor of human immunodeficiency virus (HIV) replication than was the duration or frequency of treatment interruption. In contrast with an NNRTI, consecutive missed doses of a boosted PI did not emerge as a major risk factor for HIV replication.
摘要
连续漏服可能会对使用非核苷类逆转录酶抑制剂（NNRTI）和利托那韦增效蛋白酶抑制剂（PI）的抗逆转录病毒治疗的疗效产生不同的影响。在接受增效 PI 治疗的 72 名受试者队列中，平均用药依从性是预测人类免疫缺陷病毒（HIV）复制的更好指标，而不是治疗中断的持续时间或频率。与 NNRTI 不同，连续漏服增效 PI 并未成为 HIV 复制的主要危险因素。
相似文献
1
Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication.平均依从性增强型蛋白酶抑制剂治疗，而不是漏服剂量模式，作为 HIV RNA 复制的预测指标。
Clin Infect Dis. 2010 Apr 15;50(8):1192-7. doi: 10.1086/651419.
2
Occurrence of selective ritonavir nonadherence and dose-staggering in recipients of boosted HIV-1 protease inhibitor therapy.
HIV Clin Trials. 2009 May-Jun;10(3):135-42. doi: 10.1310/hct1003-135.
3
Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.利托那韦增强型双蛋白酶抑制剂疗法在初治HIV-1感染患者中的疗效和安全性：2IP ANRS 127研究
J Antimicrob Chemother. 2009 Jul;64(1):118-25. doi: 10.1093/jac/dkp146. Epub 2009 May 6.
4
Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting.在资源有限的环境中，基于增强型蛋白酶抑制剂的治疗方案对接受基于非核苷类逆转录酶抑制剂的抗逆转录病毒治疗后出现病毒学失败的1型人类免疫缺陷病毒感染患者的疗效。
AIDS Res Hum Retroviruses. 2010 Feb;26(2):139-48. doi: 10.1089/aid.2009.0125.
5
6
CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.1型人类免疫缺陷病毒（HIV-1）感染患者的CD4 + T细胞计数恢复与抗逆转录病毒治疗的类别无关。
Clin Infect Dis. 2008 Oct 15;47(8):1093-101. doi: 10.1086/592113.
7
Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.核苷类逆转录酶抑制剂骨架对基于蛋白酶抑制剂的一线强化高效抗逆转录病毒治疗疗效的影响：5168 例患者 12 项临床试验的荟萃回归分析。
HIV Med. 2009 Oct;10(9):527-35. doi: 10.1111/j.1468-1293.2009.00724.x.
8
Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions.未计划中断治疗后的关联特征分析和阿扎那韦耐药性的发展。
HIV Med. 2014 Apr;15(4):224-32. doi: 10.1111/hiv.12107. Epub 2013 Nov 12.
9
Risk of virological failure in HIV-1-infected patients experiencing low-level viraemia under active antiretroviral therapy (ANRS C03 cohort study).接受抗逆转录病毒治疗且病毒血症水平较低的HIV-1感染患者发生病毒学失败的风险（ANRS C03队列研究）
Antivir Ther. 2015;20(6):655-60. doi: 10.3851/IMP2949. Epub 2015 Mar 4.
10
Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.拉替拉韦替代利托那韦增效的蛋白酶抑制剂治疗 HIV 感染患者：SPIRAL 研究。
AIDS. 2010 Jul 17;24(11):1697-707. doi: 10.1097/QAD.0b013e32833a608a.
引用本文的文献
1
Modeling human health behavior with a new index that measures connectivity.用一个衡量连通性的新指标对人类健康行为进行建模。
Prev Med Rep. 2023 Mar 15;33:102172. doi: 10.1016/j.pmedr.2023.102172. eCollection 2023 Jun.
2
Antiretroviral therapy non-adherence among children living with HIV in Dire Dawa, Eastern Ethiopia: a case-control study.埃塞俄比亚东部德雷达瓦市 HIV 感染儿童中的抗逆转录病毒治疗不依从性：一项病例对照研究。
BMC Pediatr. 2022 Nov 10;22(1):653. doi: 10.1186/s12887-022-03697-1.
3
Incentives and Reminders to Improve Long-term Medication Adherence (INMIND): Protocol for a Pilot Randomized Controlled Trial.改善长期药物依从性的激励与提醒措施（INMIND）：一项试点随机对照试验方案
JMIR Res Protoc. 2022 Oct 31;11(10):e42216. doi: 10.2196/42216.
4
Accuracy of measures for antiretroviral adherence in people living with HIV.抗逆转录病毒药物依从性测量在 HIV 感染者中的准确性。
Cochrane Database Syst Rev. 2022 Jul 25;7(7):CD013080. doi: 10.1002/14651858.CD013080.pub2.
5
Improvement in Bioavailability and Pharmacokinetic Characteristics of Efavirenz with Booster Dose of Ritonavir in PEGylated PAMAM G4 Dendrimers.聚乙二醇化 PAMAM G4 树枝状大分子中利托那韦增效剂提高依非韦伦的生物利用度和药代动力学特征。
AAPS PharmSciTech. 2022 Jun 25;23(6):177. doi: 10.1208/s12249-022-02315-8.
6
Forgiveness of Dolutegravir-Based Triple Therapy Compared With Older Antiretroviral Regimens: A Prospective Multicenter Cohort of Adherence Patterns and HIV-RNA Replication.基于多替拉韦的三联疗法与旧抗逆转录病毒方案相比的疗效：一项关于依从模式和HIV-RNA复制的前瞻性多中心队列研究
Open Forum Infect Dis. 2021 Jul 1;8(7):ofab316. doi: 10.1093/ofid/ofab316. eCollection 2021 Jul.
7
START (Supporting Treatment Adherence Readiness through Training) Improves Both HIV Antiretroviral Adherence and Viral Reduction, and is Cost Effective: Results of a Multi-site Randomized Controlled Trial.通过培训提高治疗依从性准备度（START）可改善 HIV 抗逆转录病毒的依从性和病毒载量降低，并具有成本效益：多中心随机对照试验结果。
AIDS Behav. 2021 Oct;25(10):3159-3171. doi: 10.1007/s10461-021-03188-x. Epub 2021 Apr 2.
8
Examining Correlates of Pre-ART and Early ART Adherence to Identify Key Factors Influencing Adherence Readiness.检查抗逆转录病毒治疗（ART）前和早期 ART 依从性的相关因素，以确定影响依从性准备的关键因素。
AIDS Behav. 2021 Jan;25(1):113-123. doi: 10.1007/s10461-020-02947-6.
9
Behavioral Economics Incentives to Support HIV Treatment Adherence (BEST): Protocol for a randomized controlled trial in Uganda.行为经济学激励支持艾滋病毒治疗依从性（BEST）：乌干达一项随机对照试验的方案。
Trials. 2020 Jan 3;21(1):9. doi: 10.1186/s13063-019-3795-4.
10
The Impact of Cumulative Depression Along the HIV Care Continuum in Women Living With HIV During the Era of Universal Antiretroviral Treatment.在普遍抗逆转录病毒治疗时代，HIV 感染者女性在 HIV 护理连续体中累积抑郁的影响。
J Acquir Immune Defic Syndr. 2019 Nov 1;82(3):225-233. doi: 10.1097/QAI.0000000000002140.
本文引用的文献
1
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.初治的HIV-1感染患者中，每日一次达芦那韦/利托那韦与洛匹那韦/利托那韦的对比：96周分析。
AIDS. 2009 Aug 24;23(13):1679-88. doi: 10.1097/QAD.0b013e32832d7350.
2
Antiretroviral medication adherence and the development of class-specific antiretroviral resistance.抗逆转录病毒药物依从性与特定类别抗逆转录病毒耐药性的发展
AIDS. 2009 Jun 1;23(9):1035-46. doi: 10.1097/QAD.0b013e32832ba8ec.
3
Rate and predictors of self-chosen drug discontinuations in highly active antiretroviral therapy-treated HIV-positive individuals.高效抗逆转录病毒治疗的HIV阳性个体自行停药的比率及预测因素。
AIDS Patient Care STDS. 2009 Jan;23(1):35-9. doi: 10.1089/apc.2007.0248.
4
Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen.基于非核苷类逆转录酶抑制剂的抑制性治疗方案中断后病毒抑制恢复及耐药性检测
AIDS. 2008 Nov 12;22(17):2279-89. doi: 10.1097/QAD.0b013e328311d16f.
5
Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study.抗逆转录病毒治疗方案的依从性水平、类型与血浆1型人类免疫缺陷病毒RNA病毒载量之间的关系：一项前瞻性队列研究。
AIDS Res Hum Retroviruses. 2008 Oct;24(10):1263-8. doi: 10.1089/aid.2008.0141.
6
Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels.并非所有漏服剂量的情况都相同：在低至中等依从性水平下，持续的非核苷类逆转录酶抑制剂（NNRTI）治疗中断可预测HIV病毒载量反弹。
PLoS One. 2008 Jul 30;3(7):e2783. doi: 10.1371/journal.pone.0002783.
7
Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy.在接受抗逆转录病毒治疗的HIV感染成人中，比较药房续方依从性与CD4细胞计数变化以进行监测。
PLoS Med. 2008 May 20;5(5):e109. doi: 10.1371/journal.pmed.0050109.
8
Implementation of the Medicare Part D prescription drug benefit is associated with antiretroviral therapy interruptions.医疗保险处方药福利计划的实施与抗逆转录病毒治疗中断有关。
AIDS Behav. 2009 Feb;13(1):1-9. doi: 10.1007/s10461-008-9401-5. Epub 2008 May 16.
9
Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance.对抗逆转录病毒联合疗法的依从性差异与产生耐药性的病毒学失败相关。
AIDS. 2008 Jan 2;22(1):75-82. doi: 10.1097/QAD.0b013e3282f366ff.
10
Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients.坚持高效抗逆转录病毒治疗（HAART）对接受非核苷类逆转录酶抑制剂（NNRTI）或蛋白酶抑制剂（PI）治疗患者的病毒学结局及耐药性突变选择的影响。
HIV Clin Trials. 2007 Sep-Oct;8(5):282-92. doi: 10.1310/hct0805-282.
Zotero 插件